{"name":"Melinta Therapeutics","slug":"melinta","ticker":"MLNT","exchange":"NASDAQ","domain":"melinta.com","description":"Melinta Therapeutics is an American biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings. The company is located in Parsippany, New Jersey.","hq":"Morristown, NJ","founded":0,"employees":"","ceo":"Johanna Mercier","sector":"Anti-Infectives / Commercial Antibiotics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$155M","metrics":{"revenue":130000000,"revenueGrowth":700.4,"grossMargin":0,"rdSpend":55409000,"netIncome":-157192000,"cash":441590000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2017-01-01","label":"Baxdela first approved","drug":"Baxdela","drugSlug":"delafloxacin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Baxdela patent cliff ($100M at risk)","drug":"Baxdela","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"Vabomere patent cliff ($200M at risk)","drug":"Vabomere","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"Orbactiv patent cliff ($150M at risk)","drug":"Orbactiv","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Baxdela","genericName":"DELAFLOXACIN","slug":"delafloxacin","indication":"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","status":"marketed"},{"name":"Orbactiv","genericName":"Orbactiv","slug":"orbactiv","indication":"Bacterial infection of skin","status":"marketed"},{"name":"Single-Dose IV Oritavancin Diphosphate","genericName":"Single-Dose IV Oritavancin Diphosphate","slug":"single-dose-iv-oritavancin-diphosphate","indication":"Acute bacterial skin and skin structure infections (ABSSSI)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Kimyrsa","genericName":"Kimyrsa","slug":"kimyrsa","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"CEM-101","genericName":"CEM-101","slug":"cem-101","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"Kimyrsa","genericName":"Kimyrsa","slug":"kimyrsa","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Baxdela","genericName":"DELAFLOXACIN","slug":"delafloxacin","phase":"marketed","mechanism":"Baxdela works by blocking bacterial enzymes that replicate DNA.","indications":["Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","Community-Acquired Bacterial Pneumonia (CABP)"],"catalyst":""},{"name":"CEM-101","genericName":"CEM-101","slug":"cem-101","phase":"phase_2","mechanism":"CEM-101 is a potent and selective inhibitor of the histone deacetylase 6 (HDAC6) enzyme.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"Orbactiv","genericName":"Orbactiv","slug":"orbactiv","phase":"marketed","mechanism":"Small molecule","indications":["Bacterial infection of skin","Staphylococcal infection of skin","Streptococcal infection of skin"],"catalyst":""},{"name":"Single-Dose IV Oritavancin Diphosphate","genericName":"Single-Dose IV Oritavancin Diphosphate","slug":"single-dose-iv-oritavancin-diphosphate","phase":"phase_3","mechanism":"Oritavancin diphosphate is a lipoglycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria.","indications":["Acute bacterial skin and skin structure infections (ABSSSI)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Melinta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Melinta Therapeutics reported its fourth quarter and full year 2023 financial results, with revenue of $24.4 million and a net loss of $34.2 million.","drugName":"","sentiment":"neutral"},{"date":"2023-10-17","type":"deal","headline":"Melinta Therapeutics Announces Exclusive Distribution Agreement with Sandoz for Baxdela","summary":"Melinta Therapeutics announced an exclusive distribution agreement with Sandoz for its antibiotic Baxdela.","drugName":"","sentiment":"positive"},{"date":"2023-05-18","type":"regulatory","headline":"FDA Approves Melinta Therapeutics' New Label for Vabomere","summary":"The FDA approved a new label for Melinta Therapeutics' antibiotic Vabomere, expanding its use to include the treatment of complicated urinary tract infections.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNWEE0SkhCVUF4SzVkM2JzUWJ2YXJneS1SckdiWm00OGYwbWJOOWtoNVBaZGJObENwTFI5NzQ2Uktvc29KNElsRjV6UG1XU1dmMnRaM1dqWTBpRFQwaDd4TFdwME12djBYZjdDUm5MMFVqbXZieF8ydThfY242czh0S19JQ0dSbVJmTVV6V21IdFpvQXYwbFVEWHZkaFo5dW5sYVZsUm1UbV9SQldiVEFPRjd2ZlAtV1VYM05felhYRF9GUUlyX01lVmt2Ylh2bFFxVHZQX2FXdlBrU2EzcTJTaFpadGJFU0VEbFRNTm9JRUl0NXBVSWRxeHNxc1hhX1JjM0tQT01RYlA2Zw?oc=5","date":"2025-08-07","type":"pipeline","source":"Business Wire","summary":"Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership - Business Wire","headline":"Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadersh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQbmJzZjFmTE1QTmNGRWRYZkZtajJoZDRSeGNYZWlodW1vOWFjTFBLSkZuaGZXcEZjaHRxUUpKa0FJbFotM05EaUZrTjM3ZDVJb3FJQTJDZUktZDBqdzZCLS1rWHNHRXVveGlwY0FSTDY4UHhZdk5nTmE4S2lMYWhsNmpaWVRnLWpXSDNGU2V5OFJvRHN3ZGY5OGZDWGhJd1ZfMWlWdEdyV1RLMGFmYVRTVG9xcFlLZG8?oc=5","date":"2021-08-05","type":"pipeline","source":"PR Newswire","summary":"Acurx Pharmaceuticals Joins the Antimicrobials Working Group - PR Newswire","headline":"Acurx Pharmaceuticals Joins the Antimicrobials Working Group","sentiment":"neutral"},{"date":"2020-04-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2020-04-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K-CONFIRMATION ORDER","headline":"SEC 8-K: 8-K-CONFIRMATION ORDER","sentiment":"neutral"},{"date":"2020-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZm5FMmRHVDRldXZ5ZmNUWG1uM0t4ZmpBTmVkcndYUW9vaFZQLXdpeXBzdy1YTUVjR0ZsTWJjNm4zNXYyaWhJRWhpdk14TklhY1BNd1ZMZ21wcHVIRmZMTE1LYURibWxVUkV5MWFFb1VrOHRCdGl2UVZNcnowWkxSOHpBZlRrZDBiYk8xbmdMQUZUUmJ3aW9xaFJSVGtRdDVDR1p1c00wY3RoMWxhT3poU3FjWkM5OWlK?oc=5","date":"2018-10-29","type":"trial","source":"investingnews.com","summary":"Melinta Therapeutics Releases Positive Trial Results - investingnews.com","headline":"Melinta Therapeutics Releases Positive Trial Results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxPNDI2OEtIeGM1TFhPd0NKYUd5TXpMbklZeXVxdHhjT0R4azBfRl9FS2tqR2NqcUtpTHJOeURndlZSY2R6YXR4MXdtSjZHY1VWeVBIdXE3NEtjYTgxaVhqM3lCZmsxWHpEMHo3czAtRXlxdGM3b3pBQV9Yb012UVJiRWlxWm9ieW1EUndOWDZhYmdtSzVzblIyMWVwMUlnRmlpWDdwRmxsSnJIb3lKbzl2bE1TaVE0aUxxdV9RMGdSS0FaYm9sWWRqdGVpZlplYzliblBzVHd5RzBDRDRNbndQeV9wQjZJelI3XzB5ZUdsWDVENF9iX1lXcDFzN25yTEs1Qmp1S3I0b2Vla2R2?oc=5","date":"2017-11-29","type":"deal","source":"globenewswire.com","summary":"Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company - globenewswire.com","headline":"Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company","sentiment":"neutral"}],"patents":[{"drugName":"Baxdela","drugSlug":"delafloxacin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Vabomere","drugSlug":"meropenem-and-vaborbactam","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":200000000},{"drugName":"Orbactiv","drugSlug":"oritavancin","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":150000000}],"drugCount":5,"phaseCounts":{"marketed":3,"phase_2":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co.","Pfizer Inc.","GlaxoSmithKline plc"],"therapeuticFocus":["Anti-infectives","Commercial antibiotics"],"financials":{"source":"sec_edgar+yahoo","revenue":33864000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":33864000,"period":"2017-12-31"},{"value":4231000,"period":"2017-12-31"},{"value":3191000,"period":"2017-09-30"},{"value":3979000,"period":"2017-06-30"},{"value":22463000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":55409000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-157192000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":441590000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}